These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 7635945)

  • 1. Dominant expression of type III hyperlipoproteinemia. Pathophysiological insights derived from the structural and kinetic characteristics of ApoE-1 (Lys146-->Glu).
    Mann WA; Lohse P; Gregg RE; Ronan R; Hoeg JM; Zech LA; Brewer HB
    J Clin Invest; 1995 Aug; 96(2):1100-7. PubMed ID: 7635945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variable expression of familial dysbetalipoproteinemia in apolipoprotein E*2 (Lys146-->Gln) Allele carriers.
    de Knijff P; van den Maagdenberg AM; Boomsma DI; Stalenhoef AF; Smelt AH; Kastelein JJ; Marais AD; Frants RR; Havekes LM
    J Clin Invest; 1994 Sep; 94(3):1252-62. PubMed ID: 8083367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apolipoprotein E isoforms and rare mutations: parallel reduction in binding to cells and to heparin reflects severity of associated type III hyperlipoproteinemia.
    Mann WA; Meyer N; Weber W; Meyer S; Greten H; Beisiegel U
    J Lipid Res; 1995 Mar; 36(3):517-25. PubMed ID: 7775863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triglyceride-rich lipoproteins of subjects heterozygous for apolipoprotein E2(Lys146-->Gln) are inefficiently converted to cholesterol-rich lipoproteins.
    Mulder M; van der Boom H; de Knijff P; Braam C; van den Maagdenberg A; Leuven JA; Havekes LM
    Atherosclerosis; 1994 Aug; 108(2):183-92. PubMed ID: 7980718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The functional characteristics of a human apolipoprotein E variant (cysteine at residue 142) may explain its association with dominant expression of type III hyperlipoproteinemia.
    Horie Y; Fazio S; Westerlund JR; Weisgraber KH; Rall SC
    J Biol Chem; 1992 Jan; 267(3):1962-8. PubMed ID: 1730728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apolipoprotein E2 (Arg136 --> Cys) mutation in the receptor binding domain of apoE is not associated with dominant type III hyperlipoproteinemia.
    März W; Hoffmann MM; Scharnagl H; Fisher E; Chen M; Nauck M; Feussner G; Wieland H
    J Lipid Res; 1998 Mar; 39(3):658-69. PubMed ID: 9548597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype.
    Kypreos KE; Li X; van Dijk KW; Havekes LM; Zannis VI
    Biochemistry; 2003 Aug; 42(33):9841-53. PubMed ID: 12924933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic heterogeneity of apolipoprotein E and its influence on plasma lipid and lipoprotein levels.
    de Knijff P; van den Maagdenberg AM; Frants RR; Havekes LM
    Hum Mutat; 1994; 4(3):178-94. PubMed ID: 7833947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic heterogeneity in familial dysbetalipoproteinemia. The E2(lys146----gln) variant results in a dominant mode of inheritance.
    Smit M; de Knijff P; van der Kooij-Meijs E; Groenendijk C; van den Maagdenberg AM; Gevers Leuven JA; Stalenhoef AF; Stuyt PM; Frants RR; Havekes LM
    J Lipid Res; 1990 Jan; 31(1):45-53. PubMed ID: 2313204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Identification of a novel mutation at the point of low density lipoprotein receptor gene from a subject with familial hypercholesterolemia].
    Liu YR; Tao QM; Chen JZ; Tao M; Guo XG; Shang YP; Zhu JH; Zhang FR; Zheng LR; Wang XX
    Sheng Li Xue Bao; 2004 Oct; 56(5):566-72. PubMed ID: 15497035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterozygosity for apolipoprotein E-4Philadelphia(Glu13----Lys, Arg145----Cys) is associated with incomplete dominance of type III hyperlipoproteinemia.
    Lohse P; Rader DJ; Brewer HB
    J Biol Chem; 1992 Jul; 267(19):13642-6. PubMed ID: 1352296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The composition, structural properties and binding of very-low-density and low-density lipoproteins to the LDL receptor in normo- and hypertriglyceridemia: relation to the apolipoprotein E phenotype.
    Dergunov AD; Novoselov AV; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V
    Biol Chem; 2005 May; 386(5):441-52. PubMed ID: 15927888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diminished LDL receptor and high heparin binding of apolipoprotein E2 Sendai associated with lipoprotein glomerulopathy.
    Hoffmann MM; Scharnagl H; Panagiotou E; Banghard WT; Wieland H; März W
    J Am Soc Nephrol; 2001 Mar; 12(3):524-530. PubMed ID: 11181800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Familial dysbetalipoproteinemia: a genetically heterogenous disease caused by mutations of the ligand apolipoprotein E.
    Vermeer BJ; Frants RR; Havekes LM
    J Invest Dermatol; 1992 Jun; 98(6 Suppl):57S-60S. PubMed ID: 1588125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apolipoprotein E-1Harrisburg: a new variant of apolipoprotein E dominantly associated with type III hyperlipoproteinemia.
    Mann WA; Gregg RE; Sprecher DL; Brewer HB
    Biochim Biophys Acta; 1989 Oct; 1005(3):239-44. PubMed ID: 2804053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of an apolipoprotein E3 variant (Arg 145-->His) associated with mild hypertriglyceridemia.
    Hidaka H; Tozuka M; Hidaka E; Yamauchi K; Ota H; Honda T; Katsuyama T
    Ann Clin Lab Sci; 2001 Apr; 31(2):163-70. PubMed ID: 11337906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Multiple molecular-genetic defects in a woman with mixed hyperlipoproteinemia and early ischemic heart disease].
    Malyshev PP; Stambol'skiĭ DV; Meshkov AN; Davydova IuV; Kukharchuk VV
    Ter Arkh; 2003; 75(10):71-4. PubMed ID: 14669611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A two-module region of the low-density lipoprotein receptor sufficient for formation of complexes with apolipoprotein E ligands.
    Fisher C; Abdul-Aziz D; Blacklow SC
    Biochemistry; 2004 Feb; 43(4):1037-44. PubMed ID: 14744149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of very low density lipoprotein production and clearance contributes to age- and gender- dependent hyperlipoproteinemia in apolipoprotein E3-Leiden transgenic mice.
    van Vlijmen BJ; van 't Hof HB; Mol MJ; van der Boom H; van der Zee A; Frants RR; Hofker MH; Havekes LM
    J Clin Invest; 1996 Mar; 97(5):1184-92. PubMed ID: 8636429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of a disease-causing Glu119-Lys mutation in the low-density lipoprotein receptor gene in two Danish families with heterozygous familial hypercholesterolemia.
    Jensen HK; Jensen TG; Jensen LG; Hansen PS; Kjeldsen M; Andresen BS; Nielsen V; Meinertz H; Hansen AB; Bolund L
    Hum Mutat; 1994; 4(2):102-13. PubMed ID: 7981713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.